{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:40:30Z","timestamp":1790419230334,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T00:00:00Z","timestamp":1180051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Pathogenic monoclonal anti\u2013double\u2010stranded DNA (anti\u2010dsDNA) antibodies up\u2010regulate the expression of lipocalin\u20102 in glomerular mesangial cells. This study was undertaken to investigate whether polyclonal anti\u2010dsDNA antibodies promote the local secretion of lipocalin\u20102 in the kidneys of patients with systemic lupus erythematosus (SLE), and whether urinary lipocalin\u20102 represents a marker of kidney involvement in SLE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Hispanic, African American, and white patients with SLE and normal healthy control subjects from affiliated hospitals of the Albert Einstein College of Medicine were recruited for this cross\u2010sectional study. Patients were classified based on the presence of active renal disease according to the SLE Disease Activity Index (SLEDAI). Correlations of clinical and laboratory data with urinary and serum levels of lipocalin\u20102 were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among SLE patients, urinary lipocalin\u20102 levels were significantly higher in those with lupus nephritis (LN) (median 17.1 ng\/mg creatinine, interquartile range [IQR] 10.3\u201345.4; n = 32) than in those without LN (median 11.2 ng\/mg creatinine, IQR 3.1\u201320.3; n = 38) (<jats:italic>P<\/jats:italic> = 0.023). Compared with the values in normal controls (median 4 ng\/ml, IQR 0\u201311.1; n = 14), urinary levels of lipocalin\u20102 in SLE patients were significantly higher (non\u2010normalized median 19.3 ng\/ml, IQR 8\u201334.2) (<jats:italic>P<\/jats:italic> = 0.004). The presence of lipocalin\u20102 in the urine of patients with LN correlated significantly with the renal SLEDAI score (<jats:italic>r<\/jats:italic> = 0.452, <jats:italic>P<\/jats:italic> = 0.009), but not with extrarenal disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The high prevalence of LN in SLE patients and the prognostic significance of kidney disease support the need for identifying early biomarkers to assess the risk of nephritis development and for following up patients with established disease. These findings indicate that urinary lipocalin\u20102 is a potential marker of the presence and severity of renal involvement in adult patients with SLE.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.22594","type":"journal-article","created":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T07:51:00Z","timestamp":1180338660000},"page":"1894-1903","source":"Crossref","is-referenced-by-count":116,"title":["Urinary lipocalin\u20102 is associated with renal disease activity in human lupus nephritis"],"prefix":"10.1002","volume":"56","author":[{"given":"Milena","family":"Pitashny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Hojaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aranow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meggan","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Putterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,5,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70262-9"},{"key":"e_1_2_6_3_2","first-page":"2046","article-title":"The benefit of early treatment with immunosuppressive agents in lupus nephritis","volume":"21","author":"Esdaile JM","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805073381906"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00022-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(03)00082-X"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2054oa"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-003-0119-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21934"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00710-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1997.4896"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365519509089604"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.3.414"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000088027.54400.C6"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)74811-X"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0055-0"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0146-y"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078452"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000093961"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22008"},{"key":"e_1_2_6_22_2","first-page":"288","article-title":"Systemic Lupus Erythematosus Disease Activity Index 2000","volume":"29","author":"Gladman DD","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29488"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03104"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7130.504"},{"key":"e_1_2_6_26_2","volume-title":"Classification and atlas of glomerular disease","author":"Churg J","year":"1982"},{"key":"e_1_2_6_27_2","first-page":"1538","article-title":"Diagnostic value of anti\u2010nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti\u2010nucleosome with anti\u2010dsDNA antibodies","volume":"33","author":"Gutierrez\u2010Adrianzen OA","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi229"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.046896"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20344"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20345"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2005.05.004"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000174182.70159.22"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390605"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000172799.03379.86"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2005.05.005"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006686514743"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000045945"},{"key":"e_1_2_6_39_2","first-page":"403","article-title":"Urinary soluble VCAM\u20101 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage","volume":"20","author":"Molad Y","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500603"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000132"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004080658"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20266"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20471"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22594","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:32:22Z","timestamp":1697049142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,25]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1002\/art.22594"],"URL":"https:\/\/doi.org\/10.1002\/art.22594","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,25]]}}}